Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 2/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.31 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077963 | 0.91 | KRAS (0.36) | KMT2AMEN1KRASSOS1NLRP3 | |
| SCHEMBL2076085 | 0.90 | KMT2A (0.37) | KMT2AMEN1KRASSOS1PDE9A | |
| SCHEMBL3767477 | 0.89 | KMT2A (0.34) | KMT2AMEN1BCDIN3DPDE9A | |
| Hydrochloric Acid SCHEMBL2078367 | 0.88 | KMT2A (0.34) | KMT2AMEN1BCDIN3DPDE9A | |
| SCHEMBL2077826 | 0.88 | PDE9A (0.39) | PDE9A | |
| SCHEMBL3767007 | 0.88 | KMT2A (0.33) | KMT2AMEN1PDE9A | |
| SCHEMBL2078487 | 0.88 | CDK2 (0.34) | KMT2AMEN1PDE9A | |
| SCHEMBL3762462 | 0.88 | KMT2A (0.33) | KMT2AMEN1PDE9A | |
| SCHEMBL2075490 | 0.88 | KMT2A (0.33) | KMT2AMEN1PDE9A | |
| Hydrochloric Acid SCHEMBL2075702 | 0.87 | KMT2A (0.32) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | claimed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | claimed |
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2024360-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | Cephalon, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008063232-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | DPYD, P2RX5, P2RX7 | KMT2A 3404/4885MEN1 3848/4885KRAS 1994/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | KMT2A 3587/4885MEN1 3595/4885KRAS 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.